News

ADT Sequencing With Radiotherapy for Nonmetastatic Prostate Cancer

11/04/2022

Findings from a pooled analysis reveal ADT sequencing significantly impacts clinical outcomes in patients with prostate cancer and concurrent/adjuvant ADT should be the standard of care in combination with prostate-only radiotherapy.

Findings from a pooled analysis...

11/04/2022

Oncology

News

Rezvilutamide Improves Survival vs Bicalutamide in Metastatic Hormone-Sensitive Prostate Cancer

10/27/2022

Allison Casey ;

In 2 interim analyses from the phase 3 CHART trial, rezvilutamide, a novel androgen-receptor inhibitor, significantly improved radiographic PFS and OS vs bicalutamide for patients with high-volume, metastatic, hormone-sensitive prostate...

In 2 interim analyses from the...

10/27/2022

Oncology

News

Continuing Enzalutamide After Progression Improves PFS in Metastatic Castration Resistant Prostate Cancer: PRESIDE Study

10/27/2022

Allison Casey ;

Results from the phase 3 PRESIDE study show that continuing enzalutamide with docetaxel and ADT after progression of metastatic castration-resistant prostate cancer is associated with improved PFS compared to placebo.

Results from the phase 3 PRESIDE...

10/27/2022

Oncology

News

FDA Approves Oral Darolutamide Tablets for Patients With Metastatic Hormone-Sensitive Prostate Cancer

08/08/2022

Allison Casey ;

On August 5, 2022, the FDA approved darolutamide tablets, taken orally, twice daily, in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

On August 5, 2022, the FDA...

08/08/2022

Oncology

Conference Coverage

LuPSMA vs Cabazitaxel for Metastatic Castration–Resistant Prostate Cancer: OS Outcomes From the TheraP Trial

06/06/2022

LuPSMA is associated with lower adverse events, higher response rates, improved patient-reported outcomes, and similar OS vs cabazitaxel for patients with metastatic castration–resistant prostate cancer who progress after docetaxel.

LuPSMA is associated with lower...

06/06/2022

Oncology

Conference Coverage

LuPSMA vs Cabazitaxel for Metastatic Castration–Resistant Prostate Cancer: OS Outcomes From the TheraP Trial

06/06/2022

LuPSMA is associated with lower...

06/06/2022

Oncology

Conference Coverage

Bicalutamide vs Novel Androgen Receptor Inhibitor for Metastatic Hormone–Sensitive Prostate Cancer

06/06/2022

Allison Casey ;

Novel oral androgen receptor inhibitor, SHR3680, significantly improved rPFS in patients with metastatic hormone–sensitive prostate cancer compared to bicalutamide, according to results from an interim analysis of the phase 3 CHART trial.

Novel oral androgen receptor...

06/06/2022

Oncology

Conference Coverage

Bicalutamide vs Novel Androgen Receptor Inhibitor for Metastatic Hormone–Sensitive Prostate Cancer

06/06/2022

Allison Casey ;

Novel oral androgen receptor...

06/06/2022

Oncology

Conference Coverage

Enzalutamide Added to Testosterone Suppression Provides OS Benefit in Metastatic Hormone–Sensitive Prostate Cancer

06/05/2022

Allison Casey ;

The addition of enzalutamide to testosterone suppression provides a clinically meaningful OS benefit over a conventional non-steroidal anti-androgen for patients with metastatic hormone-sensitive prostate cancer.

The addition of enzalutamide to...

06/05/2022

Oncology

Conference Coverage

Enzalutamide Added to Testosterone Suppression Provides OS Benefit in Metastatic Hormone–Sensitive Prostate Cancer

06/05/2022

Allison Casey ;

The addition of enzalutamide to...

06/05/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology